| Wissenschaftl. Titel | A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND) |
| Erkrankung |
Haut:
Ekzem (Dermatitis):
Neurodermitis (Atopische Dermatitis)
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Zu den Ein- und Ausschlusskriterien |
erstellt 17.07.2024 Admin07
geändert 23.07.2025 Admin02